Tada, Y, Soliman, AM, Ishii, K, Sakuma, R, Pinter, A, Davis, M, Nunag, D, Buessing, M, Puig, L, Imafuku, S. Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan. EXPERIMENTAL DERMATOLOGY. 2024; 33(5)DOI:10.1111/exd.15067. PMID:38757460. IF:3.100(Q2/3D).

Gatica-Ortega, ME, Pastor-Nieto, MA, Giménez-Arnau, AM, Mercader-García, P, Sanz-Sánchez, T, Carrascosa-Carrillo, JM, Córdoba-Guijarro, S, Sánchez-Pérez, J, Silvestre, JF, Frutos, FJOD, Tous-Romero, F, Fernández-Redondo, V, Serra-Baldrich, E, Ruíz-González, I, Pérez, RG, Miquel-Miquel, J, Guillén, PSP, Hervella-García, M, Heras-Mendaza, F, Gómez-de-la-Fuente, E, Zaragoza-Ninet, V, Gilo, AS, Rodríguez-Serna, M, Melé-Ninot, G, Descalzo, MA, de-Vega, M, García-Doval, I, Borrego, L. 2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?. CONTACT DERMATITIS. 2024; 90(5)DOI:10.1111/cod.14520. PMID:38351475. IF:4.600(Q1/1D).

Schwartzman, S, Puig, L, Cohen, AD, Khattri, S, Jossart, C, Diaz, C, Garrelts, A, Zhu, DT, Eberhart, N, Eleftheriadi, A, Tangsirisap, N, Schuster, C, Gottlieb, AB, Sheesh, M. An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis treated with ixekizumab from 26 clinical studies. RHEUMATOLOGY. 2024; 63DOI:10.1093/rheumatology/keae163.211. PMID:. IF:4.400(Q1/1D).

Mateu-Arrom, L, López-Sánchez, C, Yélamos, O. Prominent Skin Markings on the Dermoscopic Evaluation of Melanocytic Lesions: The Importance of Context. Dermatology Practical & Conceptual. 2024; 14(2)DOI:10.5826/dpc.1402a126. PMID:38810050. IF:2.300(Q2/5D).